CavGene Therapeutics

CavGene Therapeutics is an Australian biotechnology company focused on developing regenerative gene therapies for sensorineural hearing loss. The company utilizes a unique delivery platform that integrates with cochlear implant technology to deliver therapeutic DNA directly to the inner ear via electroporation. This approach aims to stimulate the regeneration of auditory nerve fibers, thereby improving the interface between the bionic ear and the auditory system. Founded on pioneering research from UNSW Sydney, CavGene works in close collaboration with industry leaders to enhance the performance of cochlear implants and address the underlying causes of deafness.